Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(20/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(20/week)
News
United States
(450/week)
Manufacturing
(348/week)
Technology
(352/week)
Energy
(230/week)
Other Manufacturing
(292/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Almotriptan
Mar 30, 2020
Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC(TM), Dosed Every Other Day, for the Preventive Treatment of Migraine
Jan 31, 2020
Lilly's REYVOW(TM) (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription
Dec 23, 2019
Allergan Receives U.S. FDA Approval for UBRELVY(TM) for the Acute Treatment of Migraine with or without Aura in Adults
Dec 23, 2019
FDA approves new treatment for adults with migraine
Dec 17, 2019
Biohaven Achieves Positive Topline Results in Pivotal Phase 2/3 Study of Vazegepant, The First and Only Intranasal CGRP Receptor Antagonist in Clinical Development for the Acute Treatment of Migraine
Dec 04, 2019
Allergan Announces Positive Phase 3 ACHIEVE I Trial Results for Ubrogepant Published in The New England Journal of Medicine
Nov 29, 2019
World Migraine Therapeutics Market Study 2019-2024 - Triptans Projected to Grow at a Healthy CAGR
Jul 11, 2019
Biohaven Showcases Positive Data on Rimegepant, Oral CGRP Receptor Antagonist, with 16 Presentations at 2019 American Headache Society (AHS) Annual Scientific Meeting Demonstrating Efficacy in Multiple Patient Types and Long-term Safety
Jun 24, 2019
Biohaven To Present 16 Abstracts At 2019 American Headache Society (AHS) Annual Scientific Meeting Highlighting New Data With Rimegepant, Oral CGRP Receptor Antagonist
Dec 10, 2018
Biohaven Announces Positive Results from Ongoing Rimegepant Long-Term Safety Study
Oct 17, 2018
Allergan Announces Completion of Two Positive Safety Studies for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Jun 28, 2018
Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig(TM) (erenumab-aooe) In Patients With Chronic And Episodic Migraine
Jun 28, 2018
Allergan's Study in Chronic Migraine Receives Migraine Research Award at the American Headache Society's 60th Annual Scientific Meeting
Jun 28, 2018
Biohaven Expands Rimegepant Development Program to Include New Prevention of Migraine Phase 3 Trial and Highlights Key Late-Breaking Presentations at American Headache Society (AHS) Annual Scientific Meeting
Jun 27, 2018
Promius Pharma Announces Migraine Presentations at the 60th Annual Scientific Meeting of the American Headache Society
Jun 11, 2018
Allergan's Oral CGRP Receptor Antagonist Atogepant Demonstrates Robust Efficacy and Safety in Episodic Migraine Prevention in a Phase 2b/3 Clinical Trial
May 17, 2018
FDA approves novel preventive treatment for migraine
Apr 27, 2018
Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant -- an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Feb 06, 2018
Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Nov 27, 2017
Biohaven Completes Enrollment In Second Pivotal Phase 3 Clinical Trial Of Oral CGRP-Receptor Antagonist Rimegepant
Page 1
››
Latest News
Mar 29, 2024
Cool Company Ltd. - Announcement Of Filing Of Form 20-F Annual Report
Mar 29, 2024
dynaCERT Provides Update on the Purchase Order for HydraGEN™ Units Destined for Guyana
Mar 29, 2024
CFIUS Accepts Re-filed Notice for Proposed Sale of The Kinetic Group to CSG
Mar 29, 2024
Cheniere Energy Partners, L.P. 2023 Annual Report
Mar 29, 2024
Aptiv to Release First Quarter 2024 Financial Results
Mar 29, 2024
Empire State Realty Trust Receives WELL Health-Safety Leadership Award; Becomes Among the First Commercial...
Mar 29, 2024
Fortive Schedules First Quarter 2024 Earnings Conference Call
Mar 29, 2024
Pacific Coast Oil Trust Announces There Will Be No March Cash Distribution
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events